Envoy Medical Inc (COCH)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$0.69-2.93%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Cash from operations improves to better than -$6M: OCF -$6.1M vs -$6.0M target.
Envoy Medical aims to control losses with operating income near -$6M in 2026-Q1. The CEO received a higher salary and equity, signaling management commitment. The company completed a $48M stock offering in early 2026. Nasdaq compliance efforts continue despite past delisting notices.
Operating losses worsened from -$4.55M in 2024-Q4 to -$5.96M in 2026-Q1. Cash flow from operations declined from -$2.81M to -$6.06M in the same period. The company faces Nasdaq delisting risks and has no revenue growth guidance. Market cap is only $58M with high risk and loss-making status.
The market values Envoy Medical near $0.38 per share with an implied growth of 25.5% over 3 years. Our fair value is $0.39, reflecting modest upside. The price reflects high risk and ongoing losses with no clear revenue growth visibility.
Breaks if: cash from operations falls below -6.0 million USD in any quarter
Control operating losses and negative cash flow while advancing clinical and regulatory milestones.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has volatile management, but it is attempting to advance its clinical trials and regulatory submissions.
The market appears to price in a high level of fragility, with an expensive valuation compared to peers. There is an expectations gap that suggests the market anticipates significant progress or changes in the company's situation.
Fundamentals are likely to remain under pressure due to ongoing operating losses and negative cash flow. However, management is making progress on clinical trials, which could provide some stability in the multi-year view.
The thesis hinges on the company's ability to manage its cash runway effectively and the outcomes of its clinical trials. Additionally, external factors like sector performance and economic conditions will play a crucial role in shaping future results.
The most important moves since the prior daily snapshot.
No, our read on the company is unchanged. H.C. Wainwright lowered its estimate on Envoy Medical to $2.00 from $2.50. This reflects a projected higher number of shares outstanding. The company reported a net loss of $7.3 million, wider than expected.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 8 of last 8 quarters. The company has consistently reported net losses ranging from $4.6 million in 2024-Q4 to $7.3 million in 2026-Q2 and negative cash flow from operations increasing from $2.6 million in 2024-Q3 to $6.1 million in 2026-Q2. Despite management focus, operating losses and cash burn remain substantial, indicating limited progress in reducing losses while advancing clinical and regulatory activities.
“Net loss attributable to common stockholders was $7.3 million; cash used in operating activities was $6.1 million.”
“Net loss was $5.7 million; cash used in operating activities was $6.1 million.”
“Net loss was $6.6 million; cash used in operating activities was $5.7 million.”
“Net loss was $6.5 million; cash used in operating activities was $4.3 million.”
“Net loss was $5.7 million; cash used in operating activities was $4.5 million.”
“Net loss was $5.0 million; cash used in operating activities was $3.7 million.”
“Net loss was $4.6 million; cash used in operating activities was $5.1 million.”
“Net loss was $6.0 million; cash used in operating activities was $2.6 million.”
Breaks if: operating income falls below -6.0 million USD in any quarter
Control operating losses and negative cash flow while advancing clinical and regulatory milestones.
Stated as a priority in 8 of last 8 quarters. The company has consistently reported net losses ranging from $4.6 million in 2024-Q4 to $7.3 million in 2026-Q2 and negative cash flow from operations increasing from $2.6 million in 2024-Q3 to $6.1 million in 2026-Q2. Despite management focus, operating losses and cash burn remain substantial, indicating limited progress in reducing losses while advancing clinical and regulatory activities.
“Net loss attributable to common stockholders was $7.3 million; cash used in operating activities was $6.1 million.”
“Net loss was $5.7 million; cash used in operating activities was $6.1 million.”
“Net loss was $6.6 million; cash used in operating activities was $5.7 million.”
“Net loss was $6.5 million; cash used in operating activities was $4.3 million.”
“Net loss was $5.7 million; cash used in operating activities was $4.5 million.”
“Net loss was $5.0 million; cash used in operating activities was $3.7 million.”
“Net loss was $4.6 million; cash used in operating activities was $5.1 million.”
Breaks if: Receipt of new delisting notice or transfer of listing
Over the next 1 to 3 years, COCH faces significant risks but also has potential catalysts in its clinical development efforts. Not investment advice.
“Net loss was $6.0 million; cash used in operating activities was $2.6 million.”